Changes to AIDS dementia complex in the era of highly active antiretroviral therapy

AIDS

Volumn 13, Issue 10, 1999, Pages 1249-1253

  Dore, Gregory J ^a   Correll, Patricia K ^a   Li, Yueming ^a   Kaldor, John M ^a   Cooper, David A ^a,b   Brew, Bruce J ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

Author keywords

AIDS dementia complex; Antiretroviral therapy; Australia; Epidemiology; HIV

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; AUSTRALIA; CENTRAL NERVOUS SYSTEM DISEASE; CRYPTOCOCCOSIS; DRUG EFFICACY; HUMAN; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TOXOPLASMOSIS;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AIDS DEMENTIA COMPLEX; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; AUSTRALIA; CD4 LYMPHOCYTE COUNT; CENTRAL NERVOUS SYSTEM DISEASES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; POPULATION SURVEILLANCE;

EID: 0032814250     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199907090-00015     Document Type: Article

References (36)

1. 1. Delta Coordinating Committe. Delta: a randomised double-blind controlled trial Comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996, 348:283-291.
2. 2. Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HlV-infected adults with CD4 tell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996, 335:1081-1090.
3. 3. CAESAR Coordinating Committee. Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet 1997, 349:1413-1421.
4. 4. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997, 337:725-733.
5. 5. Brodt HR, Kamps BS, Gute P, Knupp B, Staszewski S, Helm EB. Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy. AIDS 1997, 11:1731-1738.
6. 6. Mouton Y, Allandari S, Valette M, et al. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. AIDS 1997, 11:F101-F105.
7. 7. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998, 338:853-860.
8. 8. Hogg RS, Heath KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998, 279:450-454.
9. 9. Egger M, Hirschel B, Francioli P, et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. BMJ 1997, 315:1194-1199.
10. 10. Correll PK, Law MG, McDonald AM, Cooper DA, Kaldor JM. HIV disease progression in the time of combination antiretroviral therapies. Med J Aust 1998, 169:468-472.
11. 11. Moore R, Keruly JC, Gallant J, Chaisson RF. Decline in mortality rates and opportunistic disease with combination antiretroviral therapy. 12th World AIDS Conference. Geneva, June 1998 [abstract 22374].
12. 12. Holtzer CD, Jacobsen MA, Hadley WK, et al. Decline in specific opportunistic infections at San Francisco General Hospital. 5th Conference on Retrovirus and Opportunistic Infections. Chicago, February 1998 [abstract 103].
13. 13. Murphy R, El-Sadr W, Cheung T, Luski Hawk R, Yurik T, Neaton J, Hafner R for the CPCRA 034/ACTG 277 leam. Impact of protease inhibitor containing regimens on the risk of developing opportunistic infections and mortality in the CPCRA 034/ACTG 277 Study. 5th Conference on Retrovirus and Opportunistic Infections. Chicago, February 1498 [abstract 181].
14. 14. Huang L, Turner J, Swanson M, Holtzer C, Stansell J, Hecht F. Pneumocystis carinii pneumonia in the protease inhibitor era. 5th Conference on Retrovirus and Opportunistic Infections. Chicago, February 1998 [abstract 185].
15. 15. Hood S, Evans J, Bonington A, Henning DW. Decreasing incidence of oropharyngeal candidiasis in a HIV cohort following the introduction of proteinase inhibitors. XXXVII Intersciences Conference on Antimicrobial Agents and Chemotherapy. Toronto, September 1997 [abstract 1-28].
16. 16. Baril L, Jouan M, Caumes E, Mengual X, Bricaire F, Katlama C. The impact of highly active antiretroviral therapy on the incidence of CMV disease in AIDS patients. XXXVII Intersciences Conference on Antimicrobial Agents and Chemotherapy. Toronto, September 1997 [abstract 1-31].
17. 17. Jouan M, Cambau E, Baril L, Caumes E, Mengual X, Bricaire F, Katlama C. Decreased incidence of disseminated MAC infection in 689 AIDS patients receiving treatment with protease inhibitors. XXXVII Intersciences Conference on Antimicrobial Agents and Chemotherapy. Toronto, September 1997 [abstract 1-30].
18. 18. Le Moing V, Bissuel F, Costagliola D, et al. Decrease of intestinal cryptosporidiosis prevalence in HIV infected patients with concomitant diffusion of protease inhibitors. XXXVII Intersciences Conference on Antimicrobial Agents and Chemotherapy. Toronto, September 1997 [abstract 1-38].
19. 19. Flexner C. HIV-protease inhibitors. N Engl J Med 1998, 338:1281-1292.
20. 20. Kaldor J, McDonald AM, Blumer CF, et al. The acquired immunodeficiency syndrome in Australia: incidence 1982-1991. Med J Aust 1993, 158:10-17.
21. 21. Centers for Disease Control. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR 1987, 36 (Suppl. 1S):3S-15S.
22. 22. Australian National Council on AIDS. Definition of HIV infection and AIDS-defining illness. ANCA Bull 1994, 18:1-6.
23. 23. Centers for Disease Control. Revised classification system for HIV infection and expanded surveillance case definition for AIDS. MMWR 1992, 41 (RR-17):1-19.
24. 24. Prestage G, Grulich A, Knox S, Kaldor J, Kippax S. Uptake of antiretroviral treatments among HIV-positive gay men. 10th Annual Conference of the Australasian Society of HIV Medicine. Newcastle, Australia, November 1998 [abstract P26].
25. 25. Cuzick J. A Wilcoxon-lype test for trend. Stat Med 1985, 4:87-90.
26. 26. Dore GJ, Hoy JF, Mallal SA, et al. Trends in incidence of AIDS illnesses in Australia 1983-1994: the Australian AIDS Cohort. J Acquired Immune Defic Syndr Human Retrovirol 1997, 16:39-43.
27. 27. Hoover DR, Saah AJ, Bacellar H, et al. Clinical manifestations of AIDS in the era of Pneumocystis prophylaxis. N Engl J Med 1993, 329:1922-1926.
28. 3. J Infect Dis 1994, 170:1284-1287.
29. 29. Moore RD, Chaisson RE. Natural history of opportunistic disease in an HIV-infected urban clinical cohort. Ann Intern Med 1996, 124:633-642.
30. 30. Foudraine NA, Hoetelmans RMW, Lange JMA, et al. Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine. Lancet 1998, 351:1547-1551.
31. 31. Brew BJ, Pemberton L, Cunningham P, Law MG. Levels of human immunodeficiency virus type 1 in cerebrospinal fluid correlate with AIDS dementia stage. J Infect Dis 1997, 175:963-966.
32. 32. Brew BJ. Neurological efficacy of stavudine and lamivudine. Lancet 1998, 352:402.
33. 33. Wong JK, Ignacio CC, Torriani F, Havlir D, Fitch NJS. In vivo compartmentalization of human immunodeficiency virus: evidence from the examination of pol sequences from autopsy tissues. J Virol 1997, 71:2059-2071.
34. 34. Brew BJ, Evans L, Byrne C, Pemberton L, Hurren L. The relationship between AIDS dementia complex and the presence of macrophage tropic and non syncytium inducing isolates of human immunodeficiency virus type 1 in the cerebrospinal fluid. J Neurovirol 1996, 2:152-157.
35. 35. Simpson DM, Tagliati M. Neurologic manifestations of HIV infection. Ann Intern Med 1994, 121:769-785.
36. 36. Dromer F, Mathoulin S, Dupont B, et al. Epidemiology of cryptococcosis in France: a 9-year survey (1985-1993). Clin Infect Dis 1996, 23:82-90.